April 2022: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in April 2022 for investigational products in development.
Osteoporosis
Hidden Drugs Found in Supplements Promoted for Musculoskeletal Conditions
Laboratory analyses revealed certain Artri and Ortiga products contain undeclared drug ingredients.
Abaloparatide Looks Promising for Men With Osteoporosis
The phase 3 ATOM study evaluated the efficacy and safety of abaloparatide in 228 men with osteoporosis.
Tymlos Label Update Highlights Bone Building Mechanism of Action
The update is based on data from an open-label, single-arm histomorphometry study.
Osteoporosis Treatments Compared to Assess Effects on Bone Mineral Density
The network meta-analysis compared the effects of 9 osteoporosis drugs on BMD.
NAMS Updates Position Statement on Osteoporosis Management
Risk factor assessment can identify candidates for screening; nonpharmacologic measures appropriate for all postmenopausal women
Experts Address Osteoporosis Therapy and COVID-19 Vaccination
Oral bisphosphonates should be continued without delay; one-week interval recommended between IV bisphosphonate and vaccine
Rates of Drug Treatment for Osteoporosis Low in the US
Patterns of drug prescribing for the treatment of osteoporosis often do not follow clinical practice guidelines
Topical Corticosteroid Use and Osteoporosis Risk Examined
To determine the association between cumulative exposure of potent and very potent TCSs and osteoporosis and MOF risk, study authors utilized the Danish nationwide registries.
Corticosteroid Exposure Affects Bone Health in Asthma Patients
Oral, inhaled corticosteroid use linked to increased risk for osteoporosis, fragility fractures
